{"componentChunkName":"component---src-templates-chapter-level-1-chapter-level-1-tsx","path":"/topics/antiplatelet-treatment/have-i-got-the-right-topic/","result":{"pageContext":{"chapter":{"id":"db8ef934-0123-530e-9f34-52d23ea99e56","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","depth":1,"htmlHeader":"<!-- begin field 494baa65-5244-48e5-8458-036c555737cb --><h1>Have I got the right topic?</h1><!-- end field 494baa65-5244-48e5-8458-036c555737cb -->","summary":null,"htmlStringContent":"<!-- begin item 878b646c-967f-43a9-9f98-cdbcfd888453 --><!-- begin field 6dbc4839-a653-4007-aa36-acbc01567733 --><p>From age 16 years onwards.</p><!-- end field 6dbc4839-a653-4007-aa36-acbc01567733 --><!-- begin field 55ca9dc6-8d78-42e9-902d-f7d1832d9888 --><p>This CKS topic is largely based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Stable angina: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2016a</a>], <em>Unstable angina and NSTEMI: early management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2013a</a>], <em>Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2010a</a>], <em>Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2013b</a>], the NICE evidence summary <em>Transient ischaemic attack: clopidogrel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2013c</a>], the NICE technology appraisal <em>Ticagrelor for preventing atherothrombotic events after myocardial infarction</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2016b</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guidelines <em>Risk estimation and the prevention of cardiovascular disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">SIGN, 2017</a>], <em>Antithrombotics: indications and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">SIGN, 2013</a>] and <em>Management of stable angina</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">SIGN, 2018</a>], the Royal College of Physicians (RCP) <em>National clinical guideline for stroke</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">RCP, 2016</a>], the European Society of Cardiology (ECS)<em> 2016 European Guidelines on cardiovascular disease prevention in clinical practice</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2016</a>], and <em>2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2018a</a>].</p><p>This CKS topic covers the use of antiplatelet drugs for the prevention of cardiovascular events. The target populations are people with established cardiovascular disease (secondary prevention) and those who do not yet have clinically apparent cardiovascular disease, but are at high risk of cardiovascular events (primary prevention). This CKS topic includes prescribing information on antiplatelet drugs, which may be started in primary or secondary care and continued in the community.</p><p>This CKS topic does not cover:</p><ul><li>The use of glycoprotein IIb/IIIa inhibitors, as these can only be given by intravenous infusion to hospitalized patients who are undergoing percutaneous coronary interventions or who have been admitted with acute coronary syndrome.</li><li>The use of oral anticoagulants and antiplatelet drugs in combination after acute myocardial infarction.</li><li>Individuals who are taking anticoagulants or who have a bleeding disorder.</li></ul><p>This CKS topic supports the use of antiplatelet drugs in the following CKS topics: <a class=\"topic-reference external-reference\" href=\"/topics/angina/\">Angina</a>, <a class=\"topic-reference external-reference\" href=\"/topics/atrial-fibrillation/\">Atrial fibrillation</a>, <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>, <a class=\"topic-reference external-reference\" href=\"/topics/mi-secondary-prevention/\">MI - secondary prevention</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/stroke-tia/\">Stroke and TIA</a>.</p><p>The target audience for this CKS topic is healthcare professionals working within the NHS in the UK, and providing first contact or primary healthcare.</p><!-- end field 55ca9dc6-8d78-42e9-902d-f7d1832d9888 --><!-- end item 878b646c-967f-43a9-9f98-cdbcfd888453 -->","topic":{"id":"86dfa76b-bc1a-5d4b-bf7c-018d5d031947","topicId":"a68e1521-d84e-4abb-bb17-6186ba7a891a","topicName":"Antiplatelet treatment","slug":"antiplatelet-treatment","lastRevised":"Last revised in August 2020","chapters":[{"id":"af85e41e-4007-5daa-bc95-35aa03621ea0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"db8ef934-0123-530e-9f34-52d23ea99e56","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ebaf9360-bb92-51bc-8aba-ac3293fa1416","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b34f13e6-85f8-5c85-b2f7-5678c0779a07","slug":"changes","fullItemName":"Changes"},{"id":"9532ea0d-f7f7-5a08-9076-dedbf78ca97d","slug":"update","fullItemName":"Update"}]},{"id":"0370616e-85d0-5654-b5ad-ea9980ad8eaa","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"24bebba9-1157-505c-834d-bf255dd856a9","slug":"goals","fullItemName":"Goals"},{"id":"b1ab86f3-b045-5a24-b8ea-506ae6fa94c8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cb61b0c8-a7f6-5e31-af33-9c4ade31a493","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"19dcf0a2-d60c-5fe4-94b7-d902d7cc17f8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"758947ec-f9bc-59c9-a07f-663f738f5428","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8c16356c-f5cf-54fc-99e8-ccc08af83ec7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"30e0cacd-1816-520e-8f4a-aba760ce71f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9e23a119-ae6d-5e11-9691-ed23c4016c39","slug":"definition","fullItemName":"Definition"},{"id":"2ef5b7fd-3211-5769-8a72-083d9f8c40c8","slug":"mechanism-of-action","fullItemName":"Mechanism of action"},{"id":"ef9f4561-2787-59c9-974b-b656929c553c","slug":"indications","fullItemName":"Indications"},{"id":"7692771a-8763-57f6-b4fe-d4711f820cfb","slug":"complications","fullItemName":"Complications"}]},{"id":"d31d1a85-d8c2-5598-b7e0-e8b2da36e45c","fullItemName":"Management","slug":"management","subChapters":[{"id":"81844a0f-b280-563a-b66c-4a5dba6e1e9c","slug":"primary-prevention-of-cvd","fullItemName":"Scenario: Primary prevention of CVD"},{"id":"c2fb4ffa-788d-5d77-a694-3e30c3008d35","slug":"secondary-prevention-of-cvd","fullItemName":"Scenario: Secondary prevention of CVD"}]},{"id":"85828cd6-6943-58a7-9657-71760be76497","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d408bf47-147e-5914-ab35-c4142ec2a33e","slug":"low-dose-aspirin","fullItemName":"Low dose aspirin"},{"id":"4098d4bf-7db2-5e79-bdec-17a2bbfaca6a","slug":"clopidogrel","fullItemName":"Clopidogrel"},{"id":"d5d8e5ca-9f57-5ac9-955b-614b85700f3e","slug":"dipyridamole","fullItemName":"Dipyridamole"},{"id":"52159350-4f8e-536b-99c4-a75908d6233a","slug":"prasugrel","fullItemName":"Prasugrel"},{"id":"92100407-8f08-53c0-8df1-1e802f4dcbe9","slug":"ticagrelor","fullItemName":"Ticagrelor"}]},{"id":"ec007ae2-2b14-50b1-a091-3875c81c5adb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f54cfffb-be9e-5523-a47f-c1100845c9c4","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4ce7f1c7-df35-54c7-9f8b-b1aefe5762f1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f4d603b9-b19a-53ac-8058-8c414be0a10b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"69fb4d5c-2946-5ef6-8c7f-b5f81dd52f9c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1e16069-862f-500a-9f58-e84cb201da64","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fab694fa-9176-5402-b7b5-729a22dd611f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3852e22b-c968-5afe-81be-ac1efce390da","fullItemName":"References","slug":"references","subChapters":[]}]},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}